帕金森病的研究进展(9)
[80]JARRAYA B， BOULET S， RALPH G S， et al. Dopamine gene therapy for Parkinson’s disease in a nonhuman primate
without associated dyskinesia[J]. Sci Transl Med， 2009，1(2)：2-4.
[81]CIESIELSKA A， SAMARANCH L， SAN SEBASTIAN W， et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial[J]. PLoS One， 2017，12(2)：e0169965.
[82]SAN SEBASTIAN W， KELLS A P， BRINGAS J， et al. Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate[J]. Mol Ther Me-thods Clin Dev， 2014，1：14049.
[83]WILLIAMS A， GILL S， VARMA T， et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial)： a randomised， open-label trial[J]. Lancet Neurol， 2010，9(6)：581-591.
[84]SCHULZ-SCHAEFFER W J， MARGRAF N G， MUNSER S， et al. Effect of neurostimulation on camptocormia in Parkinson’s disease depends on symptom duration[J]. Mov Di-sord， 2015，30(3)：368-372., 百拇医药(杜希恂 姜宏)
without associated dyskinesia[J]. Sci Transl Med， 2009，1(2)：2-4.
[81]CIESIELSKA A， SAMARANCH L， SAN SEBASTIAN W， et al. Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial[J]. PLoS One， 2017，12(2)：e0169965.
[82]SAN SEBASTIAN W， KELLS A P， BRINGAS J， et al. Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate[J]. Mol Ther Me-thods Clin Dev， 2014，1：14049.
[83]WILLIAMS A， GILL S， VARMA T， et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial)： a randomised， open-label trial[J]. Lancet Neurol， 2010，9(6)：581-591.
[84]SCHULZ-SCHAEFFER W J， MARGRAF N G， MUNSER S， et al. Effect of neurostimulation on camptocormia in Parkinson’s disease depends on symptom duration[J]. Mov Di-sord， 2015，30(3)：368-372., 百拇医药(杜希恂 姜宏)